



Consistently
delivering access to
Pr Sandoz® Teriflunomide

THIS PRODUCT
IS COVERED BY
Continium™
Patient Support Program
SEE BACK FOR DETAILS



A generic equivalent
to **PrAubagio***

- > Third multiple sclerosis treatment supported by Sandoz Continium™ patient support program
- > Available in a wallet blister format with numeroted days and weeks to track medication intake

Appearance (actual size)	Strength	DIN	Format	UPC
<p>PrSandoz® Teriflunomide</p>  <p>PrAubagio*</p> 	<p>14 mg Film-coated tablets</p>	<p>02505843</p>	<p>Wallet blister of 28 tablets</p>	<p>0 57513 22187 3</p>

™ / ® Trademark and registered trademark owned or used under license by Sandoz Canada Inc.

* Registered trademark owned by its respective registrant.

Please consult Product Monograph available at sandoz.ca/en/Generics or obtain a copy by calling Sandoz Medical Information at 1-800-343-8839 ext. 4636.

SANDOZ A Novartis
Division

Sandoz Canada Inc. 110, rue de Lauzon, Boucherville (Québec) J4B 1E6
www.sandoz.ca

22-04-MKT097

**PrSandoz®
Teriflunomide**

This product is covered by

**Sandoz
Continüm™**
Patient Support Program

Support you can trust

Why choose Sandoz Continüm™?



SPEED

24-hour turnaround
for enrolment



SIMPLICITY

Easy-to-complete
enrollment form that
requires only one
signature, the
patient's consent



EFFICIENCY

Electronic coverage
speeds up payment
process

What services are offered for PrSandoz® Teriflunomide?†

Our experienced team of patient access specialists provide:



REIMBURSEMENT NAVIGATION

Regional expertise
to help complete
coverage requests



FINANCIAL ASSISTANCE

Financial support
available, tailored to
each patient's situation



EDUCATIONAL MATERIAL

Patient card and brochure,
and a checklist for
healthcare professionals



**For any questions or to obtain the enrollment form,
please contact Sandoz Continüm™ at 1-888-6-SANDOZ (726369)
or visit sandoz.ca/en/psp.**

™/® Trademark and registered trademark owned or used under license by Sandoz Canada Inc.

† Provincial exclusions may apply due to regulatory or other considerations.

PrSandoz® Teriflunomide is indicated as monotherapy for the treatment of patients with relapsing remitting multiple sclerosis (RRMS) to reduce the frequency of clinical exacerbations and to delay the accumulation of physical disability.

Please consult Product Monograph available at sandoz.ca/en/Generics or obtain a copy by calling Sandoz Medical Information at 1-800-343-8839 ext. 4636.

SANDOZ A Novartis
Division

Sandoz Canada Inc. 110, rue de Lauzon, Boucherville (Québec) J4B 1E6
www.sandoz.ca